- Home
- MTR vs CLDI Comparison
MTR vs CLDI Comparison
Compare MTR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- CLDI
- Stock Information
- Founded
- MTR 1979
- CLDI 2014
- Country
- MTR United States
- CLDI United States
- Employees
- MTR N/A
- CLDI N/A
- Industry
- MTR Oil & Gas Production
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTR Energy
- CLDI Health Care
- Exchange
- MTR Nasdaq
- CLDI Nasdaq
- Market Cap
- MTR 8.6M
- CLDI 8.7M
- IPO Year
- MTR N/A
- CLDI N/A
- Fundamental
- Price
- MTR $4.58
- CLDI $1.43
- Analyst Decision
- MTR
- CLDI
- Analyst Count
- MTR 0
- CLDI 0
- Target Price
- MTR N/A
- CLDI N/A
- AVG Volume (30 Days)
- MTR 16.0K
- CLDI 232.3K
- Earning Date
- MTR 01-01-0001
- CLDI 11-13-2025
- Dividend Yield
- MTR 4.48%
- CLDI N/A
- EPS Growth
- MTR N/A
- CLDI N/A
- EPS
- MTR 0.23
- CLDI N/A
- Revenue
- MTR $623,288.00
- CLDI N/A
- Revenue This Year
- MTR N/A
- CLDI N/A
- Revenue Next Year
- MTR N/A
- CLDI N/A
- P/E Ratio
- MTR $19.72
- CLDI N/A
- Revenue Growth
- MTR N/A
- CLDI N/A
- 52 Week Low
- MTR $4.29
- CLDI $1.10
- 52 Week High
- MTR $10.42
- CLDI $30.12
- Technical
- Relative Strength Index (RSI)
- MTR 42.77
- CLDI 42.70
- Support Level
- MTR $4.50
- CLDI $1.10
- Resistance Level
- MTR $4.69
- CLDI $1.56
- Average True Range (ATR)
- MTR 0.20
- CLDI 0.13
- MACD
- MTR 0.03
- CLDI 0.01
- Stochastic Oscillator
- MTR 47.99
- CLDI 55.93
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.